TY - JOUR
T1 - Molecular-targeted nanotherapies in cancer
T2 - Enabling treatment specificity
AU - Blanco, Elvin
AU - Hsiao, Angela
AU - Ruiz-Esparza, Guillermo U.
AU - Landry, Matthew G.
AU - Meric-Bernstam, Funda
AU - Ferrari, Mauro
N1 - Funding Information:
The authors gratefully acknowledge funding from DOD/BCRP ( W81XWH-09-1-0212 ) awarded to MF. EB gratefully acknowledges support from postdoctoral fellowships from DOD/BCRP ( W81XWH-11-1-0103 ) and the Susan G. Komen Breast Cancer Foundation (KG101394). MF serves on the Board of Directors of Arrowhead Research Corporation (NASDAQ:ARWR), Leonardo Biosystems, and NanoMedical Systems, and has a financial interest in these companies as a shareholder.
PY - 2011/12
Y1 - 2011/12
N2 - Chemotherapy represents a mainstay and powerful adjuvant therapy in the treatment of cancer. The field has evolved from drugs possessing all-encompassing cell-killing effects to those with highly targeted, specific mechanisms of action; a direct byproduct of enhanced understanding of tumorigenic processes. However, advances regarding development of agents that target key molecules and dysregulated pathways have had only modest impacts on patient survival. Several biological barriers preclude adequate delivery of drugs to tumors, and remain a formidable challenge to overcome in chemotherapy. Currently, the field of nanomedicine is enabling the delivery of chemotherapeutics, including repositioned drugs and siRNAs, by giving rise to carriers that provide for protection from degradation, prolonged circulation times, and increased tumor accumulation, all the while resulting in reduced patient morbidity. This review aims to highlight several innovative, nanoparticle-based platforms with the potential of providing clinical translation of several novel chemotherapeutic agents. We will also summarize work regarding the development of a multistage drug delivery strategy, a robust carrier platform designed to overcome several biological barriers while en route to tumors.
AB - Chemotherapy represents a mainstay and powerful adjuvant therapy in the treatment of cancer. The field has evolved from drugs possessing all-encompassing cell-killing effects to those with highly targeted, specific mechanisms of action; a direct byproduct of enhanced understanding of tumorigenic processes. However, advances regarding development of agents that target key molecules and dysregulated pathways have had only modest impacts on patient survival. Several biological barriers preclude adequate delivery of drugs to tumors, and remain a formidable challenge to overcome in chemotherapy. Currently, the field of nanomedicine is enabling the delivery of chemotherapeutics, including repositioned drugs and siRNAs, by giving rise to carriers that provide for protection from degradation, prolonged circulation times, and increased tumor accumulation, all the while resulting in reduced patient morbidity. This review aims to highlight several innovative, nanoparticle-based platforms with the potential of providing clinical translation of several novel chemotherapeutic agents. We will also summarize work regarding the development of a multistage drug delivery strategy, a robust carrier platform designed to overcome several biological barriers while en route to tumors.
KW - Cancer
KW - Liposomes
KW - Molecular therapeutics
KW - Nanomedicine
KW - Polymer micelles
KW - SiRNA
UR - http://www.scopus.com/inward/record.url?scp=81855198905&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=81855198905&partnerID=8YFLogxK
U2 - 10.1016/j.molonc.2011.10.005
DO - 10.1016/j.molonc.2011.10.005
M3 - Review article
C2 - 22071376
AN - SCOPUS:81855198905
SN - 1574-7891
VL - 5
SP - 492
EP - 503
JO - Molecular oncology
JF - Molecular oncology
IS - 6
ER -